Skip to main content

$0.040 0.004 (11.11%)

High

$0.04

Low

$0.04

Trades

37

Turnover

$81,892

Volume

2,106,389
30 June 2023 at 3:45pm
Register to track NTI and receive email alerts.
Subject
NTI Ann: Change of Director's Interest Notice x 2

NTI Ann: Application for quotation of securities - NTI

NTI Ann: NTI Receives HREC/TGA Approval for Phase II/III ASD Trial

NTI Ann: Secondary Trading Notice

NTI Ann: Application for quotation of securities - NTI

NTI Ann: Application for quotation of securities - NTI

NTI Ann: Becoming a substantial holder

NTI Ann: Notice of Annual General Meeting/Proxy Form

NTI Ann: Annual Report (Typeset)

NTI Ann: Neurotech Receives $1.2M R&D Tax Rebate

NTI Ann: Quarterly Activities/Appendix 4C Cash Flow Report

NTI Ann: Reinstatement to Quotation

NTI Ann: Investor Presentation

NTI Ann: Proposed issue of securities - NTI

NTI Ann: Neurotech Completes $9.0M Placement

NTI Ann: Suspension From Official Quotation

NTI Ann: 20 Week Data Shows Significant Improvement For ASD Children

NTI Ann: Application for quotation of securities - NTI

NTI Ann: Trading Halt

NTI Ann: Upcoming Presentation at South-West Connect ASX Showcase

NTI Ann: New Phase I/II Clinical Trial in Children with PANDAS/PANS

NTI Ann: Application for quotation of securities - NTI

NTI Ann: Proposed issue of securities - NTI

NTI Ann: Autism Spectrum Disorder Phase I/II Clinical Trial Update

NTI Ann: NTI to Present at ASX Small to Mid-Cap Investor Conference

NTI Ann: Initial Director's Interest Notice

NTI Ann: Application for quotation of securities - NTI

NTI Ann: Neurotech to present at E&P Small Cap Healthcare Conference

NTI Ann: Executive Change

NTI Ann: Appendix 4G and Corporate Governance Statement

NTI Ann: Appendix 4E & Annual Report

NTI Ann: Final Director's Interest Notice x2

NTI Ann: Proposed issue of securities - NTI

NTI Ann: Proposed issue of securities - NTI

NTI Ann: Consultant Appointment and Board Changes

NTI Ann: Change of Director's Interest Notice

NTI Ann: Quarterly Activities/Appendix 4C Cash Flow Report

NTI Ann: Q&A on NTI164 Breakthrough Clinical Trial Results in ASD

NTI Ann: Initial Director's Interest Notice

NTI Ann: Investor Presentation

NTI Ann: Investor Webinar

NTI Ann: Reinstatement to Official Quotation

NTI Ann: BREAKTHROUGH RESULTS WITH NTI164 IN PAEDIATRIC ASD

NTI Ann: Extension to Voluntary Suspension

NTI Ann: Suspension from Official Quotation

NTI Ann: Trading Halt

NTI Ann: Neurotech CEO to Present at Gold Coast Investment Showcase

NTI Ann: Proposed issue of securities - NTI

NTI Ann: Preclinical Success with Targeted Combination Therapies

NTI Ann: Investor Webinar Presentation

Register to track NTI and receive email alerts.

Similar Companies

AT1
COH
CSX
CYC
EMV
IBX
IPD
MX1
RSH
SOM